Cosmo Technologies Ltd (sponsor), 2013-02: Phase 2 registry record from the maker of methylene blue MMX tablets testing whether oral dosing causes double-stranded DNA damage in the colorectal mucosa of 10 participants. Completed with results posted.
Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
Cosmo Technologies Ltd (sponsor), 2013-02: Phase 2 registry record from the maker of methylene blue MMX tablets testing whether oral dosing causes double-stranded DNA damage in the colorectal mucosa of 10 participants. Completed with results posted. Quote is the RECORD FIELD title (this run did not open the posted results tables), hence MEDIUM. Sponsor: Cosmo Technologies Ltd (Italy). Phase 2. Status COMPLETED; enrollment 10; start 2013-02; primary completion 2014-12; HAS RESULTS posted. Registered specifically to answer the DNA-damage question raised by Olliver et al. (MTM-06), by the company that makes the product; a verifier should read the posted results table. Study type: regulatory record.
